|  |
| --- |
| **Supplementary Table 1. Patient Demographic Data for 10 Phase II and Phase III Short-term MDD Trials\*** |
| Characteristic | Placebo(n=1621) | Vortioxetine (n=2616) | Duloxetine (n=753) |
|  |  | 5 mg(n=1013) | 10 mg(n=699) | 15 mg(n=449) | 20 mg(n=455) |  |
| Sex, n (%) Male Female | 574 (35.4)1047 (64.6) | 354 (34.9)659 (65.1) | 219 (31.3)480 (68.7) | 141 (31.4)308 (68.6) | 143 (31.4)312 (68.6) | 239 (31.7)514 (68.3) |
| Race, n (%) Asian Caucasian Black/African American  Othera | 63 (3.9)1327 (81.9)225 (13.9)6 (0.4) | 69 (6.8)804 (79.4)133 (13.1)7 (0.7) | 66 (9.4)536 (76.7)88 (12.6)9 (1.3) | 6 (1.3)372 (82.9)69 (15.4)2 (0.4) | 5 (1.1)358 (78.7)87 (19.1)5 (1.1) | 39 (5.2)637 (84.6)75 (10.0)2 (0.3) |
| Age, years  Mean Minimum, maximum | 46.218, 85 | 48.018, 88 | 44.618, 75 | 44.718, 75 | 44.018,75 | 49.618, 87 |

MDD, major depressive disorder.

\*For studies included see Table 1.

a Includes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Other, and Unknown categories.

|  |
| --- |
| **Supplementary Table 2. Patient Demographic Data for 3 Long-term MDD Trials\***  |
| **Characteristic** | Total (N=1956) |
| Sex, n (%)MaleFemale | 605 (30.9)1351 (69.1) |
| Race, n (%)American Indian or Alaska NativeBlack/African American Native Hawaiian or Other Pacific IslanderAsianCaucasianOthera | 10 (0.5)332 (17.0)3 (0.2)59 (3.0)1551 (79.3)1 (<0.1) |
| Age, years MeanMinimum, maximum | 44.918, 75 |

MDD, major depressive disorder.

\*For studies included, see Table 2. N denotes number of patients in the safety set.

a Includes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Other, and Unknown categories.